GLFD Guilford Pharmaceuticals (MM)

Guilford Pharmaceuticals to Announce First Quarter 2004 Financial Results on Monday, May 10, 2004 BALTIMORE, April 27 /PRNewswire-FirstCall/ -- Guilford Pharmaceuticals Inc. will announce its first quarter 2004 financial results on Monday, May 10, 2004 before the opening of the U.S. financial markets. The company will also host a conference call and live audio webcast at 11:00 a.m. E.T. following the announcement. During this call, Guilford's management will discuss the financial results and other business for the upcoming year. The press release and live webcast can be accessed by going to the Investor Relations section of Guilford's website at http://www.guilfordpharm.com/. Following the webcast, an archived version of the call will be available until Monday, May 17, 2004. To participate in the live conference call, U.S. residents should dial 888-482-0024, international callers 617-801-9702. The participant passcode is 90913233. An audio replay of the conference call will be available for 72 hours beginning at approximately 1:00 p.m. E.T. on May 10, 2004 through 1:00 p.m. May 13, 2004. To access the replay, U.S. residents should dial 888-286-8010, (int'l callers 617-801-6888), passcode 32350709. Guilford Pharmaceuticals Inc. is a fully integrated pharmaceutical company engaged in the research, development and commercialization of products that target the hospital market. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist used for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and post-prostatectomy erectile dysfunction. Contact: Guilford Pharmaceuticals Inc. Stacey Jurchison 410.631.5022 DATASOURCE: Guilford Pharmaceuticals Inc. CONTACT: Stacey Jurchison, Guilford Pharmaceuticals Inc., +1-410-631-5022, Web site: http://www.guilfordpharm.com/ Company News On-Call: http://www.prnewswire.com/comp/112882.html

Copyright